Literature DB >> 12920418

A comparison of antidepressant response in younger and older women.

Sophie Grigoriadis1, Sidney H Kennedy, R Michael Bagby.   

Abstract

The objective of this report is to compare antidepressant response rates and tolerability in younger and older women. One hundred fifteen female outpatients who met DSM-IV criteria for major depressive disorder were evaluated before and after 8 weeks of treatment with a selective serotonin reuptake inhibitor, nefazodone, or venlafaxine. The sample was divided into younger and older groups based on age to approximate premenopausal and postmenopausal status. Eighty-six age-matched male outpatients formed the comparison group. Younger women compared with older women had significantly lower Hamilton Rating Scale for Depression scores after 8 weeks of antidepressant treatment and achieved significant higher rates of remission. There were no differences in overall drug tolerability. This pattern was not replicated in the male patients. Younger women with depression are more responsive to serotonergic antidepressants. This may relate to changes in menstrual status. Limitations of the study and implications for the role of female sex hormones are discussed. Future investigations should include measurement of reproductive hormone levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920418     DOI: 10.1097/01.jcp.0000085415.08426.c6

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  11 in total

1.  Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship.

Authors:  Roger S McIntyre; Jakub Z Konarski; Sophie Grigoriadis; Nancy C Fan; Deborah A Mancini; Kari A Fulton; Donna E Stewart; Sidney H Kennedy
Journal:  CMAJ       Date:  2005-01-04       Impact factor: 8.262

Review 2.  The impact of sex as a biological variable in the search for novel antidepressants.

Authors:  Alexia V Williams; Brian C Trainor
Journal:  Front Neuroendocrinol       Date:  2018-05-31       Impact factor: 8.606

3.  The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women.

Authors:  Susan G Kornstein; Elizabeth A Young; Annie T Harvey; Stephen R Wisniewski; Jennifer L Barkin; Michael E Thase; Madhukar H Trivedi; Andrew A Nierenberg; A John Rush
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

4.  Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

Authors:  Claudio N Soares; Michael E Thase; Anita Clayton; Christine J Guico-Pabia; Kristen Focht; Qin Jiang; Susan G Kornstein; Phillip T Ninan; Cecelia P Kane
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

5.  Does major depressive disorder change with age?

Authors:  W Coryell; D Solomon; A Leon; J G Fiedorowicz; P Schettler; L Judd; M Keller
Journal:  Psychol Med       Date:  2009-03-19       Impact factor: 7.723

6.  Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study.

Authors:  Susan G Kornstein; Marisa Toups; A John Rush; Stephen R Wisniewski; Michael E Thase; James Luther; Diane Warden; Maurizio Fava; Madhukar H Trivedi
Journal:  J Womens Health (Larchmt)       Date:  2013-02       Impact factor: 2.681

7.  Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial.

Authors:  Adina S Fischer; Bailey Holt-Gosselin; Scott L Fleming; Laura M Hack; Tali M Ball; Alan F Schatzberg; Leanne M Williams
Journal:  Neuropsychopharmacology       Date:  2020-11-23       Impact factor: 7.853

Review 8.  Sex differences in the psychopharmacological treatment of depression.

Authors:  John J Sramek; Michael F Murphy; Neal R Cutler
Journal:  Dialogues Clin Neurosci       Date:  2016-12       Impact factor: 5.986

9.  Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.

Authors:  Robyn R Jones; Marlene P Freeman; Susan G Kornstein; Kimberly Cooper; Ella J Daly; Carla M Canuso; Susan Nicholson
Journal:  Arch Womens Ment Health       Date:  2022-01-01       Impact factor: 3.633

10.  Sex difference in dopamine D1-D2 receptor complex expression and signaling affects depression- and anxiety-like behaviors.

Authors:  Ahmed Hasbi; Tuan Nguyen; Haneen Rahal; Joshua D Manduca; Sharon Miksys; Rachel F Tyndale; Bertha K Madras; Melissa L Perreault; Susan R George
Journal:  Biol Sex Differ       Date:  2020-02-22       Impact factor: 5.027

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.